KYMR · Categories · Coverage

KYMR - Analyst coverage initiated

Kymera Therapeutics Inc. (KYMR) analyst coverage initiated - real-time wire coverage filtered to Coverage only.

Recent Coverage for KYMR

• 47d
  Canaccord Genuity initiated coverage on Kymera Therapeutics with a new price target

  Canaccord Genuity initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $106.00
• 244d
  Mizuho initiated coverage on Kymera Therapeutics with a new price target

  Mizuho initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $81.00
• 278d
  Barclays initiated coverage on Kymera Therapeutics with a new price target

  Barclays initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $60.00
• 279d
  RBC Capital Mkts initiated coverage on Kymera Therapeutics with a new price target

  RBC Capital Mkts initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $70.00
• 466d
  Citigroup initiated coverage on Kymera Therapeutics with a new price target

  Citigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00
• 559d
  BTIG Research initiated coverage on Kymera Therapeutics with a new price target

  BTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00
• 563d
  BMO Capital Markets initiated coverage on Kymera Therapeutics with a new price target

  BMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00
• 581d
  Stephens initiated coverage on Kymera Therapeutics with a new price target

  Stephens initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $65.00
• 791d
  Oppenheimer initiated coverage on Kymera Therapeutics with a new price target

  Oppenheimer initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $53.00
• 858d
  Wolfe Research initiated coverage on Kymera Therapeutics

  Wolfe Research initiated coverage of Kymera Therapeutics with a rating of Peer Perform
• 1088d
  Truist initiated coverage on Kymera Therapeutics with a new price target

  Truist initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $50.00
• 1322d
  Raymond James initiated coverage on Kymera Therapeutics

  Raymond James initiated coverage of Kymera Therapeutics with a rating of Mkt Perform
• 1407d
  Jefferies initiated coverage on Kymera Therapeutics with a new price target

  Jefferies initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $40.00
• 1419d
  Goldman initiated coverage on Kymera Therapeutics with a new price target

  Goldman initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $40.00
• 1433d
  SVB Leerink initiated coverage on Kymera Therapeutics with a new price target

  SVB Leerink initiated coverage of Kymera Therapeutics with a rating of Mkt Perform and set a new price target of $26.00
• 1516d
  Credit Suisse initiated coverage on Kymera Therapeutics with a new price target

  Credit Suisse initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $63.00
• 1565d
  JP Morgan initiated coverage on Kymera Therapeutics with a new price target

  JP Morgan initiated coverage of Kymera Therapeutics with a rating of Neutral and set a new price target of $44.00
• 1593d
  Wells Fargo initiated coverage on Kymera Therapeutics with a new price target

  Wells Fargo initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $62.00
• 1726d
  B. Riley Securities initiated coverage on Kymera Therapeutics with a new price target

  B. Riley Securities initiated coverage of Kymera Therapeutics with a rating of Neutral and set a new price target of $67.00
• 1726d
  Stifel initiated coverage on Kymera Therapeutics with a new price target

  Stifel initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $80.00
• 1858d
  UBS initiated coverage on Kymera Therapeutics with a new price target

  UBS initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $80.00
• 1895d
  Berenberg initiated coverage on Kymera Therapeutics

  Berenberg initiated coverage of Kymera Therapeutics with a rating of Buy

Other KYMR categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 4
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings